AR064545A1 - Formas cristalinas de glyt1 [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il]-[5-metanosulfonil-2-((s)-2,2,2-trifluor-1-metil-etoxi)-fenil]-metanona - Google Patents

Formas cristalinas de glyt1 [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il]-[5-metanosulfonil-2-((s)-2,2,2-trifluor-1-metil-etoxi)-fenil]-metanona

Info

Publication number
AR064545A1
AR064545A1 ARP070105913A ARP070105913A AR064545A1 AR 064545 A1 AR064545 A1 AR 064545A1 AR P070105913 A ARP070105913 A AR P070105913A AR P070105913 A ARP070105913 A AR P070105913A AR 064545 A1 AR064545 A1 AR 064545A1
Authority
AR
Argentina
Prior art keywords
trifluor
fluor
piperazin
phenyl
methyl
Prior art date
Application number
ARP070105913A
Other languages
English (en)
Spanish (es)
Inventor
Urs Schwitter
Emmanuel Pinard
Andre Gerard Bubendorf
Annette Deynet-Vucenovic
Ralph Diodone
Olaf Grassmann
Kai Lindenstruth
Franziska Rohrer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38988312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR064545(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR064545A1 publication Critical patent/AR064545A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
ARP070105913A 2006-12-28 2007-12-27 Formas cristalinas de glyt1 [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il]-[5-metanosulfonil-2-((s)-2,2,2-trifluor-1-metil-etoxi)-fenil]-metanona AR064545A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06127269 2006-12-28

Publications (1)

Publication Number Publication Date
AR064545A1 true AR064545A1 (es) 2009-04-08

Family

ID=38988312

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105913A AR064545A1 (es) 2006-12-28 2007-12-27 Formas cristalinas de glyt1 [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il]-[5-metanosulfonil-2-((s)-2,2,2-trifluor-1-metil-etoxi)-fenil]-metanona

Country Status (33)

Country Link
US (5) US20080214561A1 (enExample)
EP (1) EP2114405B1 (enExample)
JP (1) JP4799666B2 (enExample)
KR (1) KR101130146B1 (enExample)
CN (1) CN101573114A (enExample)
AR (1) AR064545A1 (enExample)
AU (1) AU2007341356B2 (enExample)
BR (1) BRPI0720829B8 (enExample)
CA (1) CA2673667A1 (enExample)
CL (1) CL2007003830A1 (enExample)
CO (1) CO6190613A2 (enExample)
CR (1) CR10846A (enExample)
CY (1) CY1116350T1 (enExample)
DK (1) DK2114405T3 (enExample)
EC (1) ECSP099471A (enExample)
ES (1) ES2535040T3 (enExample)
HR (1) HRP20150573T1 (enExample)
HU (1) HUE025032T2 (enExample)
MA (1) MA31029B1 (enExample)
MX (1) MX2009006859A (enExample)
MY (1) MY188367A (enExample)
NO (1) NO342150B1 (enExample)
NZ (1) NZ577502A (enExample)
PE (1) PE20081556A1 (enExample)
PL (1) PL2114405T3 (enExample)
PT (1) PT2114405E (enExample)
RS (1) RS53910B1 (enExample)
RU (1) RU2463295C2 (enExample)
SI (1) SI2114405T1 (enExample)
TW (1) TWI388552B (enExample)
UA (1) UA100232C2 (enExample)
WO (1) WO2008080821A1 (enExample)
ZA (1) ZA200904423B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573114A (zh) 2006-12-28 2009-11-04 弗·哈夫曼-拉罗切有限公司 结晶形式glyt1
JP6074142B2 (ja) * 2009-02-26 2017-02-01 タール ファーマシューティカルズ,インコーポレイテッド 医薬化合物の結晶化
KR101196354B1 (ko) * 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
EP2855462A1 (en) * 2012-05-25 2015-04-08 Basf Se Crystalline form b of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2h-benzo[b][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione
US8927412B1 (en) * 2013-08-01 2015-01-06 Taiwan Semiconductor Manufacturing Company, Ltd. Multi-chip package and method of formation
MX354615B (es) * 2013-10-02 2018-03-08 Centro De Investig Y De Estudios Avanzados Del I P N Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus.
KR20220125326A (ko) 2020-01-09 2022-09-14 디스크 메디슨, 인크. 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법
WO2022014397A1 (ja) * 2020-07-13 2022-01-20 日本碍子株式会社 精製方法
AU2022273051A1 (en) * 2021-05-14 2023-12-07 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
AU2022283357A1 (en) * 2021-05-27 2023-12-07 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154370A0 (en) 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
UA85194C2 (ru) * 2003-08-11 2009-01-12 Ф.Хоффманн-Ля Рош Аг Пиперазины с or-замещенной фенильной группой и их применение как ингибиторов glyt 1
CN101573114A (zh) 2006-12-28 2009-11-04 弗·哈夫曼-拉罗切有限公司 结晶形式glyt1

Also Published As

Publication number Publication date
US20080214561A1 (en) 2008-09-04
PT2114405E (pt) 2015-06-02
BRPI0720829B8 (pt) 2021-05-25
AU2007341356A1 (en) 2008-07-10
US8039473B2 (en) 2011-10-18
CY1116350T1 (el) 2017-03-15
BRPI0720829A2 (pt) 2014-02-25
TW200833677A (en) 2008-08-16
AU2007341356B2 (en) 2013-08-29
UA100232C2 (uk) 2012-12-10
CN101573114A (zh) 2009-11-04
BRPI0720829B1 (pt) 2020-04-07
NZ577502A (en) 2012-02-24
KR101130146B1 (ko) 2012-03-28
CA2673667A1 (en) 2008-07-10
PL2114405T3 (pl) 2015-08-31
MX2009006859A (es) 2009-07-03
CO6190613A2 (es) 2010-08-19
SI2114405T1 (sl) 2015-06-30
CR10846A (es) 2009-08-12
RS53910B1 (sr) 2015-08-31
CL2007003830A1 (es) 2008-07-11
ZA200904423B (en) 2010-05-26
HUE025032T2 (en) 2016-02-29
HRP20150573T1 (xx) 2015-07-03
PE20081556A1 (es) 2008-11-28
US20130197225A1 (en) 2013-08-01
ECSP099471A (es) 2009-07-31
JP4799666B2 (ja) 2011-10-26
KR20090094166A (ko) 2009-09-03
EP2114405B1 (en) 2015-03-11
DK2114405T3 (en) 2015-04-07
RU2463295C2 (ru) 2012-10-10
US20110295007A1 (en) 2011-12-01
MA31029B1 (fr) 2009-12-01
ES2535040T3 (es) 2015-05-04
NO20092358L (no) 2009-06-22
TWI388552B (zh) 2013-03-11
US20120309969A1 (en) 2012-12-06
US20100311971A1 (en) 2010-12-09
JP2010514725A (ja) 2010-05-06
EP2114405A1 (en) 2009-11-11
WO2008080821A1 (en) 2008-07-10
NO342150B1 (no) 2018-04-03
MY188367A (en) 2021-12-06
RU2009124113A (ru) 2011-02-10

Similar Documents

Publication Publication Date Title
AR064545A1 (es) Formas cristalinas de glyt1 [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il]-[5-metanosulfonil-2-((s)-2,2,2-trifluor-1-metil-etoxi)-fenil]-metanona
ECSP066358A (es) PIPERAZINA CON GRUPO FENIL OR-SUSTITUIDO Y SU USO COMO INHIBIDORES GlyT1
NO20060768L (no) 1-(2-amino-benzol)-piperazinderivater som glycinopptaks-inhibitorer for behandling av psykoser
EA200501222A1 (ru) Дигидроптеридиноны, способ их получения и их применение в качестве лекарственных средств
WO2007058583A3 (en) Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies
TN2011000493A1 (en) 1-heterocyclyl -1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin -4- one derivatives and their use as pde9a modulators
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
CY1117663T1 (el) Παραγωγα 6,7-διυδρο-πυραζολο[1,5-α]πυραζιν-4-υλαμινης χρησιμα ως αναστολεις β-σεκρετασης (bace)
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
WO2015095337A3 (en) PYRAZOLO[1,5-a]PYRIMIDINECARBOXAMIDE DERIVATIVES FOR TREATING COGNITIVE IMPAIRMENT
ATE393764T1 (de) Polymorphe formen von valsartan
CU20090184A7 (es) Compuestos amino-heterocíclicos
DK1507775T3 (da) Heterocykliske forbindelser som hæmmer leukocyt-adhæsion medieret af alfa-4-integriner
BRPI0515528A (pt) n-metil hidroxietilamina úteis no tratamento de condições do sistema nervoso central
MX2019007100A (es) Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso.
ATE501153T1 (de) Kristallisation von festen formen von clopidogreladditionssalzen
DE602007013275D1 (de) Verbindungen mit kombinierten cannabinoid-cb1-antagonismus und acetylcholinesterasehemmung
ATE465986T1 (de) Substituierte cyclopentane oder cyclopentanone zur behandlung von augenhochdruck
DE602007012272D1 (de) Difluorierte piperidine zur behandlung von morbus alzheimer und verwandten leiden
DE602004026597D1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
EA200701856A1 (ru) Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
ATE524171T1 (de) Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion bei der behandlung der parkinson-krankheit
AR055111A1 (es) Sal benzoato de 4-(5-metiloxazolo (4,5-metiloxazolo (4,5- b]piridin -2-il) -1,4- diabiciclo (3.2.2) nonano
RU2007125380A (ru) Сульфанил-замещенные фенилметаноны в качестве ингибиторов переносчика глицина 1 (glyt-1) для лечения неврологических и психоневрологических заболеваний
TH107358A (th) รูปผลึกร่วมเมธิลพาราเบน A ของ [4-(3-ฟลูออโร-5-ไตรฟลูออโรเมธิล-ไพริดิน-2-อิล)- พิเพอราซิน-1-อิล]-[5-มีเธนซัลโฟนิล-2-((S)-2,2,2-ไตรฟลูออโร-1-เมธิล-เอธอกซี)-ฟีนิล]-เมธาโนน ([4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone)

Legal Events

Date Code Title Description
FC Refusal